More Genzyme Supply Trouble
New manufacturing problems at Genzyme Corp.'s Allston Landing plant may mean patients will miss doses of the drug Fabrazyme.
In a notice to patients on its website, the Cambridge-based biotech company, which has major operations in MetroWest, said a batch of finished vials of the drug was rejected during quality assurance. It said it plans to move the "fill and finish" part of the manufacturing process to a contract manufacturing facility for all future batches of the drug.
Genzyme said patients who use Fabrazyme to treat Fabry disease, a rare genetic disorder, may need to delay infusions, and possibly miss doses of the drug over the next few months.
The company said it should be able to return to a normal supply of the drug in the second half of the year, assuming its new manufacturing facility in Framingham is approved.
Genzyme, which is in the process of being acquired by French drug maker Sanofi-Aventis, had to shut down drug production in Allston in 2009 because of viral contamination.
WBJ Web Partners
Most Recent
Most Recent
0 Comments